trimetrexate has been researched along with Carcinoma, Bronchogenic in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fossella, FV | 1 |
| Winn, RJ | 1 |
| Holoye, PY | 1 |
| Hallinan, B | 1 |
| Raber, MN | 1 |
| Hoelzer, K | 1 |
| Young, JA | 1 |
| Readling, J | 1 |
| Bowers, B | 1 |
| Hong, WK | 1 |
1 trial available for trimetrexate and Carcinoma, Bronchogenic
| Article | Year |
|---|---|
Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; | 1992 |